评估1cp-LSD提高庇护犬的福利:1cp-LSD提高庇护犬的福利:1cp-LSD提高庇护犬的福利:1cp-LSD提高庇护犬的福利:1cp-LSD提高庇护犬的福利:1cp-LSD提高庇护犬的福利:1cp-LSD提高庇护犬的福利:1cp
Elisa Hernández-Álvarez1,2,3, Cristina Canino-Quijada4,5, Sira Roiz4
1Unit of Toxicology, Clinical Sciences Department, Universidad de Las Palmas de Gran Canaria, Paseo Blas Cabrera Felipe s/n, 35016 Las Palmas de Gran Canaria, Spain.
Veterinary sciences
|January 28, 2026
概括
将低剂量1-cyclopropionyl lysergic acid diethylamide (1cp-LSD) 与生理干预相结合,显著改善了庇护犬的行为和福利. 这些对焦虑和社交能力的积极影响在治疗后持续.
科学领域:
- 兽医行为医学 兽医行为医学
- 迷幻研究 迷幻研究
- 动物福利科学 动物福利科学
背景情况:
- 收容所的狗经历了慢性压力和焦虑,影响了他们的福利和可收养性.
- 迷幻药辅助疗法在兽医中表现有前途,但证据有限.
- 1-cyclopropionyl lysergic acid diethylamide (1cp-LSD) 是LSD的一种lysergamide原药. 这是一种LSD的原药.
研究的目的:
- 评估低剂量1cp-LSD和伦理干预 (EI) 对庇护所狗的行为和福利的综合影响.
- 与单个干预或对照相比,评估联合治疗的影响.
- 为了确定治疗效益的持续时间.
主要方法:
- 20只收容所的狗被随机分配到四个组:1cp-LSD,EI,联合治疗或对照.
- 兽医行为学家领导的伦理学会议由兽医行为学家领导.
- 1cp-LSD (10微克) 进行了口服治疗,持续了3周,对之前,期间和之后进行了盲目评估.
主要成果:
- 组合1cp-LSD和EI组在社交性,冷静性和积极情绪反应性方面表现出明显更大的改善.
- 综合治疗的效果优于单一干预.
- 治疗停止后,行为改善持续了三周.
结论:
- 初步证据表明,将低剂量迷幻药与行为治疗相结合,可以使庇护所狗受益.
- 这种方法可能为在避难所环境中管理压力和焦虑提供了一种新的策略.
- 需要进一步研究更大的样本大小和药理动力学数据,以确认安全性和优化协议.
相关概念视频
03:00Self-Evaluation: Self-Enhancement and Self-Verification
5.8K
Social psychologists have documented that feeling good about ourselves and maintaining positive self-esteem is a powerful motivator of human behavior (Tavris & Aronson, 2008). In the United States, members of the predominant culture typically think very highly of themselves and view themselves as good people who are above average on many desirable traits (Ehrlinger, Gilovich, & Ross, 2005). Often, our behavior, attitudes, and beliefs are affected when we experience a threat to our...
5.8K
02:07Blind Procedures
13.4K
Ideally, the people who observe and record the children’s behavior are unaware of who was assigned to the experimental or control group, in order to control for experimenter bias. Experimenter bias refers to the possibility that a researcher’s expectations might skew the results of the study. Remember, conducting an experiment requires a lot of planning, and the people involved in the research project have a vested interest in supporting their hypotheses. If the observers knew which...
13.4K
01:11Blinding
3.9K
Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
3.9K
01:03Nursing Interventions I: Taxonomy of Nursing Interventions
3.7K
Nursing interventions are chosen as part of the planning process to achieve patient outcomes. Once nursing diagnoses are determined, the goals and outcomes are specified, then the nursing interventions are selected and individualized according to the patient's situation.
A nursing intervention is a treatment or action based on scientific concepts and knowledge from the nursing, behavioral, and physical sciences. Identifying and prioritizing nursing interventions based on the desired outcome...
A nursing intervention is a treatment or action based on scientific concepts and knowledge from the nursing, behavioral, and physical sciences. Identifying and prioritizing nursing interventions based on the desired outcome...
3.7K
01:29Nursing Interventions II: Selecting and Classifying the Nursing Interventions
3.2K
Creating and executing a nursing diagnosis helps nurses plan care and guide patient, family, and community interventions. They are developed based on a patient's physical evaluation and support measuring the outcomes. It is not recommended to select random interventions throughout the planning process. Instead, consider the following six essential factors when choosing interventions:
3.2K
01:11Clinical Trials: Overview
4.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.9K